Kiadis Pharma N.V. announced that it has expanded its presence in the United States. The company also announced the appointment of Scott Holmes as chief financial officer and Amy Sullivan as senior vice president of corporate affairs, both effective January 1, 2019. Ms. Sullivan will replace Karl Hård, who resigned effective December 31, 2018, to pursue other interests.

Ms. Sullivan joins Kiadis from Keryx Biopharmaceuticals where she was senior vice president of corporate affairs, responsible for all aspects of investor relations, corporate communication, and public affairs, during a period of high growth, commercialization of the company's first FDA-approved medicine and, ultimately, a merger. She will be responsible for investor relations, corporate communications and public affairs for Kiadis.